Chemistry:SCHEMBL19952957
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H18N2O3 |
| Molar mass | 322.364 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SCHEMBL19952957 is an oxadiazole based antibiotic, originally developed in 2014 as a potential treatment for infections with methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic resistant bacteria. Subsequently, it has been found to be useful against Clostridium difficile as it not only kills active bacteria, but also inhibits the germination of the dormant spores which can otherwise often lead to persistent infections that repeatedly recur upon cessation of antibiotic treatment. While it is still only being researched in animals at this stage, this dual action is a significant advance over existing antibiotics, and it is likely that drugs from this class may be developed as new medications for the treatment of antibiotic resistant infections in humans.[1][2][3][4]
See also
References
- ↑ Chang M, Mobashery S, Spink E, Ding D, Testero S, Leemans E, Boudreau M, "Non-beta lactam antibiotics", US patent 10662164, issued 26 May 2020, assigned to University of Notre Dame.
- ↑ Chang M, Mobashery S, Ding D, "Compounds for the treatment of Clostridium difficile infection", US patent 11168062, issued 9 November 2021, assigned to University of Notre Dame.
- ↑ "A dual-action antibiotic that kills Clostridioides difficile vegetative cells and inhibits spore germination". Proceedings of the National Academy of Sciences of the United States of America 120 (20): e2304110120. May 2023. doi:10.1073/pnas.2304110120. PMID 37155891. Bibcode: 2023PNAS..12004110J.
- ↑ "Dual-action antibiotic found that kills C. difficile, preventing reinfections.". Medical Xpress. 9 May 2023. https://medicalxpress.com/news/2023-05-dual-action-antibiotic-difficile-reinfections.html.
 |  |
